Company profile
Argenica Therapeutics
Developing novel neuroprotective therapeutics
- Industry
- Pharmaceutical Manufacturing
- Employees
- 8
- Headquarters
- Nedlands, Perth, Western Australia
- Founded
- 2019
- LinkedIn followers
- 2,900
- Office locations
- 1
Argenica Therapeutics company summary
Argenica Therapeutics is a company in the Pharmaceutical Manufacturing industry, headquartered in Nedlands, Perth, Western Australia, founded in 2019. On LinkedIn the company has around 8 employees and 2,900 followers.
What technology does Argenica Therapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Argenica Therapeutics
Argenica Therapeutics(ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Stroke is the leading cause of death and disability worldwide and the economic costs of treatment and post-stroke care are substantial. With current treatments, 20% of sufferers die and 50% are left permanently disabled. Moreover, the burden of stroke is increasing with an aging population and the ongoing epidemics of cardiovascular disease, diabetes and obesity. Current treatment options remain limited to restoring blood flow through clot removal by tPA (alteplase) thrombolysis and mechanical thrombectomy. Despite considerable research, there are no marketed drugs capable of protecting the brain from damage following stroke. Therefore, the search for widely applicable and effective neuroprotective drugs for stroke patients remains an urgent unmet need and priority. Argenica has developed a neuroprotective drug that can be administered in the field by paramedics, and used in conjunction with endovascular therapy (thrombolysis/thrombectomy) to improve neuroprotective outcomes, and importantly increase the number of patients amenable to thrombolysis and thrombectomy. Specifically, Argenica has developed a neuroprotective therapeutic, ARG-007, that • Slows brain tissue death due to inadequate blood supply • Preserves brain cells and axons • Extends the treatment time window for stroke patients • Is not toxic • Can be delivered in the field by first responders The Company also intends to explore the development and commercialisation of cationic arginine-rich peptides in other neural injury conditions such as perinatal hypoxia, traumatic brain injury, spinal cord injury, and in patients undergoing endovascular procedures that carry a risk of dislodging material from a diseased artery or triggering an embolus to lodge in a brain artery and thereby causing a stroke.
Where is Argenica Therapeutics located?
Argenica Therapeutics lists 1 location.
Compare companies similar to Argenica Therapeutics
More companies in Pharmaceutical Manufacturing.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Argenica Therapeutics argenica.com.au | Pharmaceutical Manufacturing | 8 | 2019 | Nedlands, Perth, Western Australia |
 Anacor Pharmaceuticals pfizer.com | Pharmaceutical Manufacturing | 108,102 | - | New York, New York |
 Sanofi sanofi.com | Pharmaceutical Manufacturing | 93,352 | - | Paris, France, FR |
 GSK gsk.com | Pharmaceutical Manufacturing | 92,179 | - | London, England |
 Novartis España novartis.com | Pharmaceutical Manufacturing | 85,373 | - | Basel, Baselstadt |
 AstraZeneca astrazeneca.com | Pharmaceutical Manufacturing | 80,667 | - | Cambridge, Cambridgeshire, GB |
 Eli Lilly and Company lilly.com | Pharmaceutical Manufacturing | 57,202 | - | Indianapolis, Indiana |
 Merck merck.us | Pharmaceutical Manufacturing | 44,794 | - | Rahway, New Jersey |
 SUN PHARMA sunpharma.com | Pharmaceutical Manufacturing | 47,764 | 1983 | Mumbai, Maharastra |
 Boehringer Ingelheim boehringer-ingelheim.com | Pharmaceutical Manufacturing | 47,150 | - | Ingelheim am Rhein, Rhineland-Palatinate |
 Cipla cipla.com | Pharmaceutical Manufacturing | 51,911 | - | Mumbai, Maharashtra |
Frequently asked questions about Argenica Therapeutics
What does Argenica Therapeutics do?
Argenica Therapeutics(ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Stroke is the leading cause of death and disability worldwide and the economic costs of treatment and post-stroke care are substantial. With current treatments, 20% of sufferers die and 50% are left permanently disabled. Moreover, the burden of stroke is increasing with an aging population and the ongoing epidemics of cardiovascular disease, diabetes and obesity. Current treatment options remain limited to restoring blood flow through clot removal by tPA (alteplase) thrombolysis and mechanical thrombectomy. Despite considerable research, there are no marketed drugs capable of protecting the brain from damage following stroke. Therefore, the search for widely applicable and effective neuroprotective drugs for stroke patients remains an urgent unmet need and priority. Argenica has developed a neuroprotective drug that can be administered in the field by paramedics, and used in conjunction with endovascular therapy (thrombolysis/thrombectomy) to improve neuroprotective outcomes, and importantly increase the number of patients amenable to thrombolysis and thrombectomy. Specifically, Argenica has developed a neuroprotective therapeutic, ARG-007, that • Slows brain tissue death due to inadequate blood supply • Preserves brain cells and axons • Extends the treatment time window for stroke patients • Is not toxic • Can be delivered in the field by first responders The Company also intends to explore the development and commercialisation of cationic arginine-rich peptides in other neural injury conditions such as perinatal hypoxia, traumatic brain injury, spinal cord injury, and in patients undergoing endovascular procedures that carry a risk of dislodging material from a diseased artery or triggering an embolus to lodge in a brain artery and thereby causing a stroke.
How many employees does Argenica Therapeutics have?
Argenica Therapeutics has around 8 employees on LinkedIn.
Where is Argenica Therapeutics headquartered?
Argenica Therapeutics is headquartered in Nedlands, Perth, Western Australia.
When was Argenica Therapeutics founded?
Argenica Therapeutics was founded in 2019.
Build a lead list from companies like Argenica Therapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.